Clinical trials: Relapsed/ Refractory Multiple Myeloma
Multiple Myeloma and Plasma Cell Neoplasm
AE-941 in Treating Patients With Relapsed or Refractory Multiple Myeloma
RATIONALE: AE-941 may help to slow the growth of multiple myeloma. PURPOSE: Phase II trial to study the effectiveness of neovastat in treating patients who have relapsed or refractory multiple myeloma.
- Trial name
- NCT00022282
- Testing
- shark cartilage extract AE-941
- Where
- Canada
- Sponsor
- AEterna Zentaris
Multiple Myeloma
A Study Of Daratumumab, Low-Dose Oral Dexamethasone and Cyclophosphamide With Or Without Pomalidomide
This is a randomized phase II open label study of daratumumab, weekly low-dose oral cyclophosphamide and dexamethasone with or without pomalidomide in patients with relapsed and refractory multiple myeloma.
- Trial name
- DCDP (NCT03215524)
- Testing
- DCdP, DCd+P
- Where
- 11 sites in Canada
- Volunteers
- 120 people
- Sponsor
- Canadian Myeloma Research Group
Multiple Myeloma
Evaluation of IGM-2644 in Adults With Relapsed and/or Refractory Multiple Myeloma
This is a first in human, phase 1, multicenter, open-label study to determine the safety and tolerability of IGM-2644 as a single agent in participants with relapsed and/or refractory MM, for whom standard therapy does not exist…
- Trial name
- NCT05908396
- Testing
- IGM-2644
- Where
- 5 sites in United States
- Volunteers
- 4 people
- Sponsor
- IGM Biosciences, Inc.
Graft Versus Host Disease, Leukemia
Donor T Cells in Treating Patients With High-Risk Hematologic Cancer Undergoing Donor Peripheral Blood Stem Cell Transplant
RATIONALE: A donor peripheral stem cell transplant helps stop the growth of cancer cells. When the healthy stem cells from a donor are infused into the patient they may help the patient's bone marrow make stem cells, red blood…
- Conditions
- Graft Versus Host Disease, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00725062
- Testing
- CD4+CD25+ regulatory T cells, allogeneic hematopoietic stem cell transplantation
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Multiple Myeloma, Multiple Myeloma in Relapse
Safety and Tolerability Study of SNS01-T in Relapsed or Refractory B Cell Malignancies (Multiple Myeloma, B Cell Lymphoma, or Plasma Cell Leukemia (PCL)
The purpose of this study is to determine how well SNS01-T is tolerated by relapsed or refractory multiple myeloma, B cell lymphoma or plasma cell leukemia patients when given by intravenous infusion at various doses.
- Conditions
- Multiple Myeloma, Multiple Myeloma in Relapse, Mantle Cell Lymphoma in Relapse, Diffuse Large B Cell Lymphoma in Relapse
- Trial name
- NCT01435720
- Testing
- SNS01-T
- Where
- 7 sites in United States, South Africa
- Volunteers
- 15 people
- Sponsor
- Senesco Technologies, Inc.
Relapsed/Refractory Multiple Myeloma
Study to Evaluate the Safety, Tolerance, Pharmacokinetics and Preliminary Efficacy of IBI346#CIBI346Y002#
An open label, single-arm clinical study evaluating the safety and efficacy of IBI346 infusion in relapsed/refractory multiple myeloma
- Trial name
- NCT05266768
- Testing
- IBI346
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Chunrui Li
Cancer
A Structured Walking Program or Standard Therapy in Cancer Patients Undergoing a Donor Bone Marrow Transplant
RATIONALE: A walking program may improve the ability to carry out daily activities after donor bone marrow transplant. PURPOSE: This randomized clinical trial is studying a structured walking program to see how well it works…
- Trial name
- NCT00445731
- Testing
- exercise intervention, management of therapy complications, observation
- Volunteers
- 115 people
- Sponsor
- University of Minnesota
Multiple Myeloma
Safety and Efficiency Study of BCMA-PD1-CART Cells in Relapsed/Refractory Multiple Myeloma
This is a single center, non-randomized, open-label, phase 2 study to evaluate the efficacy and safety of BCMA-PD1-CART cells therapy for patients with relapsed/refractory Multiple Myeloma.
- Trial name
- NCT04162119
- Testing
- BCMA-PD1-CART Cell
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Chinese PLA General Hospital
Relapsed, Refractory
A Dose Escalating Study of CD19/CD22/BCMA CAR-T Therapy in Relapsed/ Refractory Multiple Myeloma
This is a single arm, open-label, dose escalation clinical study to evaluate the safety and tolerability of autologouschimeric antigen receptor T (CAR-T) cells targeting CD19/CD22/BCMA in patients with relapsed/refractory…
- Conditions
- Relapsed, Refractory, Multiple Myeloma
- Trial name
- NCT06732232
- Testing
- CD19/CD20/BCMA CAR-T
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Shanghai Cell Therapy Group Co.,Ltd
Neoplasms
Letetresgene Autoleucel Engineered T Cells Alone and in Combination With Pembrolizumab in NY-ESO-1 Positive Multiple Myeloma
This trial will evaluate safety, tolerability, and efficacy of letetresgene autoleucel (GSK3377794) with or without pembrolizumab in participants with relapsed and refractory multiple myeloma.
- Trial name
- NCT03168438
- Testing
- Letetresgene autoleucel, Letetresgene autoleucel with pembrolizumab, Fludarabine
- Where
- 5 sites in United States
- Volunteers
- 6 people
- Sponsor
- GlaxoSmithKline
Multiple Myeloma, Relapse
Isa-Pom-Dex in Elderly/Frail Subjects With RRMM
This research study aims to evaluate the safety and effectiveness of the combination of isatuximab, pomalidomide, and dexamethasone (Isa-Pd) for the treatment of relapsed or refractory multiple myeloma (RRMM), which refers to…
- Conditions
- Multiple Myeloma, Relapse, Refractory, Aging
- Trial name
- NCT05911321
- Testing
- Isatuximab, Pomalidomide, Dexamethasone
- Where
- 2 sites in United States
- Volunteers
- 6 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Multiple Myeloma
Study to Investigate Alternative Dosing Regimens of Belantamab Mafodotin in Participants With Relapsed or Refractory Multiple Myeloma
This study aims to evaluate alternative dosing regimens of single-agent belantamab mafodotin in participants with relapsed or refractory multiple myeloma (RRMM) to determine if an improved overall benefit/risk profile can be…
- Trial name
- DREAMM 14 (NCT05064358)
- Testing
- Belantamab mafodotin
- Where
- 77 sites in United States, Argentina and 16 more
- Volunteers
- 177 people
- Sponsor
- GlaxoSmithKline
Relapsed or Refractory Diffuse Large B Cell Lymphoma (DLBCL), Relapsed or Refractory Multiple Myeloma (MM)
Low-Dose TBI Plus CAR T-Cell Therapy for Relapsed/Refractory DLBCL and Multiple Myeloma
This is a clinical trial to evaluate the safety of combining CAR T-cell therapy with low-dose total body irradiation (LD-TBI) in patients with previously treated large B-cell lymphoma (LBCL) or multiple myeloma (MM).
- Trial name
- Prime REMIX (NCT07725406)
- Testing
- Lymphodepleting chemotherapy: Cyclophosphamide, Lymphodepleting chemotherapy: Bendamustine, Lymphodepleting chemotherapy: Fludarabine
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Weill Medical College of Cornell University
Multiple Myeloma
A Study of the Combination of Talquetamab and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
The purpose of this study is to identify the recommended Phase 2 regimen(s) (RP2R[s]) and schedule for the study treatment (Part 1), to characterize the safety of the RP2R(s) for the study treatment (Part 2) and to evaluate the…
- Trial name
- RedirecTT-1 (NCT04586426)
- Testing
- Talquetamab, Teclistamab
- Where
- 40 sites in United States, Australia and 5 more
- Volunteers
- 228 people
- Sponsor
- Janssen Research & Development, LLC
Multiple Myeloma, Refractory Multiple Myeloma
Cabozantinib as a Targeted Strategy to Reverse Carfilzomib Resistance in Refractory Multiple Myeloma
In the currently proposed phase I/II study, the investigators aim to treat patients with relapsed and/or relapsed refractory Multiple Myeloma who have progressed on carfilzomib-based therapy with an FDA approved c-MET inhibitor…
- Conditions
- Multiple Myeloma, Refractory Multiple Myeloma, Relapsed/Refractory Multiple Myeloma
- Trial name
- NCT03201250
- Testing
- Cabozantinib
- Where
- 2 sites in United States
- Volunteers
- 11 people
- Sponsor
- University of Nebraska
Chronic Myeloproliferative Disorders, Leukemia
NMA Allogeneic Hematopoietic Cell Transplant in Hematologic Cancer/Disorders
RATIONALE: Giving low doses of chemotherapy before a donor peripheral blood stem cell transplant helps stop the growth of cancer cells. It also stops the patient's immune system from rejecting the donor's stem cells.
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00053989
- Testing
- anti-thymocyte globulin, graft-versus-tumor induction therapy, sargramostim
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- Roswell Park Cancer Institute
Multiple Myeloma
Phase Ib Study of SAR650984 in Combination With Carfilzomib for Treatment of Relapsed or Refractory Multiple Myeloma
This phase Ib trial studies the side effects and best dose of isatuximab when given together with carfilzomib with or without dexamethasone and lenalidomide in treating patients with multiple myeloma that has returned after a…
- Trial name
- NCT02332850
- Testing
- Isatuximab, Carfilzomib, Dexamethasone
- Where
- 6 sites in United States, Canada
- Volunteers
- 83 people
- Sponsor
- Thomas Martin, MD
Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
Genetically Engineered Cells (MUC1-Activated T-Cells) for the Treatment of MUC1 Positive Recurrent or Refractory Multiple Myeloma
This phase I trial tests the safety, side effects and best dose of MUC1-activated T cells in treating patients with multiple myeloma that has come back (relapsed) or does not respond to treatment (refractory) and is positive for…
- Trial name
- NCT05411497
- Testing
- Autologous MUC1-activated T-cells, Cyclophosphamide
- Where
- 2 sites in United States
- Volunteers
- 5 people
- Sponsor
- Mayo Clinic
Relapsed and/or Refractory Multiple Myeloma
Carfilzomib Thalidomide and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma
All patients with multiple myeloma (MM) are destined to relapse even with the best available approved agents. Median OS from diagnosis in the current era is reported at 5.4 years.
- Trial name
- NCT03140943
- Testing
- Carfilzomib, Thalidomide and Dexamethasone
- Where
- 4 sites in Hong Kong, Singapore and 2 more
- Volunteers
- 100 people
- Sponsor
- National University Hospital, Singapore
Multiple Myeloma
A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide
The purpose of this study is to compare the effectiveness of either talquetamab plus pomalidomide (Tal-P) or talquetamab plus teclistamab (Tal-Tec) with elotuzumab, pomalidomide, and dexamethasone (EPd) or pomalidomide…
- Trial name
- MonumenTAL-6 (NCT06208150)
- Testing
- Talquetamab, Pomalidomide, Teclistamab
- Where
- 242 sites in United States, Argentina and 25 more
- Volunteers
- 838 people
- Sponsor
- Janssen Research & Development, LLC
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.